Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Non Operating Income (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Non Operating Income for 15 consecutive years, with $59000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Income fell 93.62% to $59000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$7.1 million, a 502.26% decrease, with the full-year FY2024 number at $1.7 million, up 34240.0% from a year prior.
  • Non Operating Income was $59000.0 for Q3 2025 at Plus Therapeutics, down from $6.7 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $6.7 million in Q2 2025 to a low of -$13.9 million in Q1 2025.
  • A 5-year average of -$397500.0 and a median of $2500.0 in 2023 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: skyrocketed 9362.5% in 2024, then tumbled 36586.84% in 2025.
  • Plus Therapeutics' Non Operating Income stood at -$225000.0 in 2021, then skyrocketed by 61.78% to -$86000.0 in 2022, then skyrocketed by 158.14% to $50000.0 in 2023, then crashed by 106.0% to -$3000.0 in 2024, then soared by 2066.67% to $59000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Non Operating Income are $59000.0 (Q3 2025), $6.7 million (Q2 2025), and -$13.9 million (Q1 2025).